Biopharmaceutical Contract Manufacturing Market Biopharmaceutical Contract Manufacturing Learn how outsourcing trends in biopharma m ...

The global cell counting market, valued at US$10.82 billion in 2023, is forecasted to grow at a robust CAGR of 7.7%, reaching US$11.12 billion ...

Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 millionReceived CE Mark for LungFit PH® in ...

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, ...

The firm's Protein Sciences segment saw revenues increase 7 percent, while the Diagnostics and Spatial Biology segment's revenues rose 12 percent.

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

Core Illumina revenue of $1.1 billion for Q4 2024, up 1% from Q4 2023 on both a reported and constant currency basis; revenue of $4.3 billion for fiscal year 2024, down 2% from fiscal year 2023 on ...

Less than 20 years after the first biopharmaceutical, insulin, was approved, a new generation of products is superseding replacement proteins and enzyme therapies in biotechnology's pipeline.

The 3D cell culture industry is poised for substantial growth from 2025 to 2035, driven by advancements in biotechnology and an increasing emphasis on more accurate and relevant in vitro models.